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Malaria is a major global health problem that kills 1-2 million people each year. Despite exhaustive research, naturally acquired
immunity is poorly understood. Cry1A proteins are potent immunogens with adjuvant properties and are able to induce strong
cellular and humoral responses. In fact, it has been shown that administration of Cry1Ac protoxin alone or with amoebic lysates
induces protection against the lethal infection caused by the protozoa Naegleria fowleri. In this work, we studied whether Cry1Ac
is able to activate the innate immune response to induce protection against Plasmodium berghei ANKA (lethal) and P. chabaudi
AS (nonlethal) parasites in CBA/Ca mice. Treatment with Cry1Ac induced protection against both Plasmodium species in terms
of reduced parasitaemia, longer survival time, modulation of pro- and anti-inﬂammatory cytokines, and increased levels of
speciﬁc antibodies against Plasmodium. Understanding how to boost innate immunity to Plasmodium infection should lead to
immunologically based intervention strategies.
1.Introduction
Each year, malaria infects approximately 500 million people
and kills one to two million people, mainly children below
the age of ﬁve years [1]. Despite decades of research on
the subject, naturally acquired immunity to Plasmodium
is still poorly understood [2–4]. There are reports about
the immunosuppressive eﬀects of Plasmodium infection in
humans [5] and in animal models [6]. It is believed that
the initial interaction of the parasitised red blood cells with
the host immune system is one of the most important
factors in determining the nature of the subsequent innate
and acquired response, and in determining whether or not
severe pathology, such as cerebral malaria, severe anaemia,
or cachexia, results [7–9].
On the other hand, insecticidal proteinaceous crystals
called Cry proteins are produced as protoxins by Bacillus
thuringiensis (Bt) during sporulation. Upon ingestion, crys-
talline protoxins are solubilised and proteolytically activated
by midgut proteases of susceptible insects. The activated
toxin, which is not toxic to vertebrates, binds to speciﬁc
receptors on the brush-border membrane surface of the
midgut epithelium of the insect, inducing the formation
of pores and eventually leading to insect mortality [10].
In particular, Cry1Ac is a pore-forming protein that is
speciﬁcally toxic to lepidopteran insect larvae and acts
by binding to the cell-surface receptor aminopeptidase N
in the Manduca sexta midgut via the sugar N-acetyl-D-
galactosamine (GalNAc) [11, 12].
Although most studies on Cry proteins have been
performed with regard to their toxicity in insects, we have
described that recombinant Cry1Ac protoxin from Bacillus
thuringiensis is a potent mucosal and systemic immunogen
with adjuvant properties [13, 14].2 Journal of Biomedicine and Biotechnology
In addition, we have shown that recombinant Cry1A
toxins possess the ability to induce serum and mucosal
speciﬁc antibody responses as well as to modulate IgG
subclasses due to their strong immunogenic properties [14,
15].Furthermore,ithasbeendemonstratedthatCryproteins
from B. thuringiensis can induce strong cellular immune
responses. In particular, we have described that these toxins
are able to promote IFN-γ responses [16]. In malaria
infections,aninitialIFN-γ response,mainlyproducedbyNK
cells, is implicated in the activation of macrophages, which
leads to parasite elimination [17, 18]. In a previous study,
we found that administration of the immunogenic protein
with adjuvant properties, Cry1Ac protoxin alone or with
amoebic lysates, markedly increased protective immunity
against experimental N. fowleri meningoencephalitis in mice
[13]. In this work, we determined the ability of Cry1Ac
protoxin to activate the innate immune response. So we
tested whether the pretreatment with the protein alone
improved the resistance of mice to Plasmodium chabaudi AS
and P. berghei ANKA experimental infections.
2.MaterialsandMethods
2.1. Mice and Parasites. CBA/Ca mice were kindly donated
by Dr. W Jarra (National Institute for Medical Research,
London). The mice were bred, fed, and maintained in a
speciﬁc, pathogen-free environment at the FES Zaragoza,
Universidad Nacional Aut´ onoma de M´ exico animal house
facility in accordance with the institutional and national
oﬃcial guideline NOM-062-ZOO-1999 for use and care of
laboratory animals.
P. chabaudi AS and P. berghei ANKA were donated by
Dr. William Jarra (National Institute for Medical Research,
London).
2.2. Infection and Treatment. Batches of 6 to 8 sex- and age-
m a t c h e d( 6 – 8w e e k s )C B A / C am i c ew e r et r e a t e dw e e k l yw i t h
Cry1Ac protoxin (5μg/mouse i.p.) or with vehicle (PBS)
during four weeks. One day after the last treatment, mice
were inoculated intravenously with either 5×104P. chabaudi
AS- or 5 × 104P. berghei ANKA-parasitised erythrocytes.
On the days indicated, mice were sacriﬁced under ether
anaesthesia. As controls, a parallel batch of noninfected mice
was divided into two groups and treated with PBS or Cry1Ac
at the same dose. Data presented are representative of two
separate experiments.
2.3. Blood Sampling. Parasitaemias were evaluated daily by
examination of Giemsa-stained blood smears. Numeration
of the parasitaemia was performed under oil, using a Zeiss
Standard 20 microscope (Carl Zeiss Ltd., Welwyn Garden
City). Parasitaemias of 0.5% and above were determined by
counting the number of parasitised erythrocytes present in a
total of 200 red blood cells. Lower levels of parasitaemia were
assessed by counting the number of parasitised erythrocytes
present in 50 ﬁelds. The course of infection in each group
is shown as the geometric mean of the percentage of
parasitaemia.
2.4. Recombinant Cry1Ac Escherichia coli JM103 (pOS9300).
The recombinant Cry1Ac E. coli JM103 (pOS9300) strain
was kindly donated by Dr. Dean, from Ohio State University.
The bacteria were grown in Luria-Bertani medium contain-
ing 50μg/mL of ampicillin, and Cry1Ac production was
induced with 1mM isopropyl-β-D-thiogalactopyranoside
(IPTG) [19]. Recombinant Cry1Ac was puriﬁed from the
IPTG-induced E. coli JM103 (pOS9300) cultures as follows.
Cell pellets harvested by centrifugation were suspended
in 50mM Tris-HCl, 50mM EDTA (pH 8) (TE buﬀer)
and sonicated (Fisher Sonic Dismembrator Model 300)
three times for 5 minutes on ice. Inclusion bodies were
collected by centrifugation at 10000 × gf o r1 0m i n u t e s ,
and pellets were washed twice with TE buﬀer, twice with
0.5M NaCl, and once with 0.5M/NaCl-1% Triton X-100,
once with 0.5M NaCl, once with cold distilled water and
were ﬁnally solubilised in CBP buﬀer (0.1M Na2CO3,
1% 2-mercaptoethanol [pH 9.6]). Particulate material was
discarded by centrifugation at 10000 × g for 10min, and
the puriﬁed solubilised protoxin was stored at 4◦Ca n d
examined by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). The protein concentration was
determined using the Bradford method [20]. The presence
ofendotoxincontaminationintheCry1Acprotoxinprepara-
tions was tested using the E-toxate, Part 1 kit (Sigma), which
has a sensitivity limit of 0.05–0.1 endotoxin units (EU)/mL,
following the manufacturer’s instructions. Endotoxin levels
in the puriﬁed Cry1Ac protoxin preparations were below
0.1EU/mL. These preparations were further treated with an
excess of a polymyxin B resin (Bio-Rad, Hercules CA, USA)
to remove any possible remnants of endotoxin.
2.5. Cytokine mRNA Expression. Groups of CBA/Ca mice
were treated weekly with Cry1Ac protoxin or with PBS for
four weeks. Twenty-four hours after the last inoculation,
mice were infected with either P. chabaudi AS or P. berghei
ANKA. On the days indicated, three mice of each group
were sacriﬁced under ether anaesthesia, and spleen mRNA
was extracted using Trizol (Invitrogen, Carlsbad, CA, USA).
DNA was digested with DNase I (Invitrogen) according to
the manufacturer’s instructions, and RNA was quantiﬁed
spectrophotometrically at 260nm. Next, 1.5μgo fR N A
were retrotranscribed using 1.5μg of oligo dT (Invitrogen),
0.5mM dNTPs (Pharmacia, Uppsala, Sweden), 40U RNase
inhibitor, and 200 U MMLV-RT (Invitrogen). Next, 1μLo f
the resulting cDNA was used to amplify IFN-γ and TGF-
β by PCR. Each sample was ampliﬁed in duplicate using a
previously described method [21].
Each set of primers as well as the cDNA concentration
was optimized for a number of cycles to obtain amplicons
in the linear phase of ampliﬁcation. The following gene-
speciﬁc primer sequences were used: (IFN-γ)f o r w a r d :5  
TGC ATC TTG GCT TTG CAG CTC TTC CTC ATG GC
3 , reverse 5  TGG ACC TGT GGG TTG TTG ACC TCA
TTG GC 3 ;( T G F - β)f o r w a r d5   GAC CGC AAC AAC
GCC ATC TA 3  reverse 5  GGC GTA TCA GTG GGG
GTC AG 3 ;( β-actin) forward 5  GTG GGC CGC TCT
AGG CAC CAA 3 , reverse 5  CTC TTT GAT GTC ACGJournal of Biomedicine and Biotechnology 3
CAC GAT TTC 3 . PCR reactions were performed in a total
volume of 20μL. Ampliﬁcation was carried out in 50mM
KCl, 10mM Tris-HCl (pH 8.3), 0.1mg/mL gelatin, 200mM
of each dNTP, 2mM MgCl2, 100nM of each primer, 0.5U
AmpliTaqpolymerase(AppliedBiosystems,Branchburg,NJ,
USA), and 15 ng of cDNA. The β-actin gene and either IFN-
γ or TGF-β were then simultaneously ampliﬁed in a single
tube.After27–29cycles,thePCRproductswereseparatedon
5% polyacrylamide gels and stained with ethidium bromide.
Each band was analysed by densitometry, and the results are
shown as the relation of the absorbance of the corresponding
cytokine to that of β-actin in the same sample.
2.6. Cytokine Serum Measurement. On days indicated, mice
from both the P chabaudi AS- and the P. berghei ANKA-
infected groups were sacriﬁced under ether anaesthesia.
Immediately, blood from the heart was extracted and then
centrifuged at 2000 × ga t4 ◦C for 15min. The serum was
removed and aliquoted into two tubes and snap frozen at
−70◦C until used.
The levels of the cytokines interleukin-2 (IL-2),
interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-γ
(IFN-γ), and tumour necrosis factor- (TNF-α) in the serum
samples were measured using a cytometric bead array
performed according to the manufacturer’s instructions (BD
Mouse Th1/Th2 Cytokine CBA Kit Biosciences-Pharmingen,
Heidelberg, Germany) with the following modiﬁcations.
We performed all steps in microtubes, and we started the
standard curve at a concentration of 0.625pg/mL. The
sensitivity achieved with these minor adaptations to the
protocol was 0.9±0.05pg/mL while the variation inter-assay
was approximately 5%.
2.7. Measurement of Protective Antibodies. Antibody-speciﬁc
responses were evaluated using a previously described
method [21].
A lysate of pRBC was used as the capture antigen; it was
prepared as follows. P. chabaudi AS- or P. berghei ANKA-
infected mice (25% parasitaemia) were bled into PBS-
heparinat4◦Ctoprovideparasitisederythrocytes.Theblood
was passed through a CF11 cellulose powder (Whatman,
Maidstone, UK) column to remove leukocytes and then
washed three times with PBS by centrifugation at 750 × gf o r
15min at 4◦C. The ﬁnal cell pellet was resuspended to 5mL
in PBS, and 3μL of 10% (w/v) saponin in PBS was added
to lyse the erythrocyte membranes. After centrifugation at
18,000 × gf o r5m i na t4 ◦C, the supernatant was removed,
the pellets were resuspended to 3mL in PBS, and the
cells were lysed by ultrasonication for 3 seconds with 21%
amplitude (Ultrasonic Processor Model GE750, USA). The
protein concentration of the lysates was determined using a
Bio-Rad commercial reagent, and the lysate was diluted in
carbonate-buﬀered solution to give a coating concentration
of 10μg/mL. A volume of 100μL/well was applied to ﬂat-
bottomed 96-well ELISA plates (Corning USA). First, the
plates were washed with 0.05% (v/v) Tween 20 in PBS, and
then the excess binding sites were blocked using a solution of
3% skim milk in PBS for 2 hours at 37◦C .T h ep l a t e sw e r e
then incubated with test sera in duplicate for 1h at 37◦Ca n d
diluted to 1/20 in PBS. Plates were washed extensively before
detection of parasite-speciﬁc Abs using goat antimouse
horseradish peroxidase-conjugated monoclonal Abs (mAb)
speciﬁc to IgG1, IgG2a, IgG2b, IgG3, total IgG, or IgM
(Zymed, San Francisco California, USA) diluted in 0.02%
skim milk, 0.05% Tween 20 in PBS to previously calibrated
dilutions, which were applied to plates for 1h at 37◦C.
Plates were washed before incubation with a streptavidin
peroxidase solution (diluted 1 : 3000 in 0.05% Tween 20
in PBS) before the ﬁnal wash. Plates were developed with
ortho phenylenediamine at 0.4mg/mL in citrate buﬀer (pH
5) with 0.03% of hydrogen peroxide as a substrate and
incubated in the dark at room temperature for 20min.
Absorbance was determined at 492nm by measurement
of optical density (OD) using a Stat-Fax 2100 microplate
reader (Awareness Technology Inc, USA). No standard of
knownconcentrationforeachIgisotypewasavailable.Hence
results were expressed directly as OD 492nm values and
compared to an internal standard of normal CBA mouse
serum obtained from eight- to ten-week-old naive female
mice. This internal standard provided a background value of
nonspeciﬁc responsiveness to the lysate used.
2.8. Statistical Analysis. Statistical analysis was performed
with the Stat Graphs software (version 5.1). Diﬀerences
between groups were tested for statistical signiﬁcance by
nonparametric analysis of variance (Kruskal-Wallis). A P
value <.05 was considered signiﬁcant. All data are expressed
as the mean ± S.D. Each experiment was performed in
duplicate.
3. Results
3.1. Cry1Ac Treatment Decreases Parasitaemia in CBA/Ca
Mice Infected with Plasmodium chabaudi AS or P. berghei
ANKA. Groups of CBA/Ca mice were injected once weekly
for four weeks with Cry1Ac protoxin or PBS as described in
the Materials and Methods. One day after the last injection,
mice were intravenously infected either with P. chabaudi AS
or with P. berghei ANKA. Mice treated with Cry1Ac protoxin
prior to P. chabaudi AS infection developed a moderate
parasitaemia that increased from day 6 postinfection (PI)
to reach a peak of 27% at day 10 PI. Parasitaemia resolved
spontaneously and was cleared by day 15PI. In contrast,
control mice treated with vehicle (PBS) developed higher
parasitaemias from day 6 to 15PI (signiﬁcantly (P<. 05)
from days 8 to 11PI) compared to mice treated with Cry1Ac
protoxin. Parasitaemia reached a peak of 40% at day 10, and
the parasite was completely cleared at day 16PI, one day later
than in the group of mice treated with Cry1Ac (Figure 1(a)).
In contrast, infection with P. berghei ANKA was lethal.
In control CBA/Ca mice treated with vehicle (PBS),
parasitaemia increased from day 5 PI to reach a peak of
23% at day 8 PI. There was a slight decrease in parasitaemia
at day 9, and then mice started to die on day 10 PI with
parasitaemias around 20%, conﬁrming the reported lethality
of this strain [22, 23]. Infected mice previously treated with4 Journal of Biomedicine and Biotechnology
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Figure 1: Eﬀect of Cry1Ac on parasitaemia in CBA/Ca mice.
Groups of eight mice were treated with Cry1Ac protoxin once a
week for four weeks. One day after the last injection, mice were
infected with P. chabaudi AS (a) or P. berghei ANKA (b). Groups
of control mice were treated with PBS. Data are representative of
two separate experiments.
the protoxin Cry1Ac developed lower levels of parasitaemia
than PBS-treated mice from days 7 to 9 PI; the number of
parasites in their blood decreased on day 10 PI and then
started to rise slowly. Half of this group of mice survived
until day 20 PI with parasitaemias of approximately 40%
(Figures 1(b) and 2).
3.2. Cry1Ac Protoxin Increases Survival in Plasmodium-
Infected Mice. Despite the fact that Plasmodium chabaudi AS
is not considered to be lethal, infection with this parasite
could be fatal for 10% to 20% of CBA/Ca mice. Interestingly,
mice treated with Cry1Ac and infected with P. chabaudi
AS had a survival rate of 100% compared to mice treated
with PBS, which had a survival rate of 80%. On the other
hand, mice treated with Cry1Ac and infected with the lethal
parasite P. berghei ANKA showed an increased survival of 12
days compared to control mice treated with PBS, which died
at day 9 PI (Figure 2).
3.3. Cry1Ac Protoxin Modulates Cytokine mRNA Expression
in Splenocytes from Malaria-Infected Mice. RT-PCR analysis
was performed to determine the levels of cytokine mRNA
expressioninsplenocytesfrominfectedanduninfectedmice.
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Figure 2: Eﬀe c to fC r y 1 A co nt h es u r v i v a lo fPlasmodium-infected
mice. Cry1Ac pretreated mice (n = 8) were infected with P.
chabaudi AS or P. berghei ANKA. Survival was recorded until day
21 PI, at which time all of the P. berghei ANKA-infected mice had
died. Data are representative of two separate experiments.
C e l l sw e r eo b t a i n e da td a y s4a n d8P Iw i t hP. berghei
ANKA and at days 8 and 18 PI with P. chabaudi AS. The
levels of cytokine mRNA expression were normalised to β-
actin mRNA levels, which was used as an internal standard.
Moderate, constitutive mRNA expression of IFN-γand TGF-
β was detected in control mice receiving the vehicle, while in
uninfected mice treated with Cry1Ac, similar levels of these
cytokines were recorded (Figure 3).
In P. berghei ANKA-infected mice that previously had
been administered Cry1Ac protoxin, increased levels of IFN-
γ mRNA expression were detected at days 4 and 8 PI
compared to infected mice receiving just the vehicle or
uninfected mice. At day 4 PI, similar levels of TGF-β were
found in both infected groups (slightly higher than those in
uninfected mice). In contrast, at day 8 PI, the levels of TGF-
βmRNA were lower in mice pretreated with Cry1Ac protoxin
than in those receiving just the vehicle (Figures 3(a) and
3(c)).
In control mice infected with P. chabaudi AS, the levels
of IFN-γ mRNA at days 8 and 18 PI were higher than those
in mice pretreated with Cry1Ac protoxin, which exhibited
IFN-γ levels akin to those in uninfected mice. On the other
hand, the mRNA levels of TGF-β recorded in P. chabaudi AS-
infected mice did not change signiﬁcantly either by infection
or by pretreatment with Cry1Ac protoxin.
3.4. Cry1Ac Modiﬁes Cytokine Levels in Sera from
Plasmodium-Infected Mice. The levels of cytokines (IFN-γ
andIL-4)inserumsamplesweremeasuredwithacytometric
bead array. Samples were obtained at days 4 and 8 or 8 and
18 postinfection with P. berghei ANKA and P. chabaudi AS,
respectively.
The levels of IFN-γ were signiﬁcantly increased at day 8
PI with P. berghei ANKA in mice pretreated with Cry1Ac,
conﬁrming the RT-PCR results. At day 4 postchallenge,Journal of Biomedicine and Biotechnology 5
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Figure 3: Eﬀect of Cry1Ac on the mRNA expression of IFN-γ (a and b) and TGF-β (c and d) in mice infected with P. chabaudi AS or P.
berghei ANKA. Mice were treated with Cry1Ac protoxin or PBS as a control. One day after the last injection, mice were infected with P.
berghei ANKA or P. chabaudi AS. On days 4 and 8 PI (a and c) or days 8 and 18 PI (b and d), three mice from each group were killed, and
theirsplenicmRNAwasextractedandretrotranscribed.ThecDNAobtainedwasusedtoamplifytheβ-actingeneandeitherIFN-γ orTGF-β
by PCR in the same tube. PCR products were separated on 5% polyacrylamide gels. Bands were analysed by densitometry, and the results
are shown as the absorbance of the corresponding cytokine divided by the absorbance of β-actin. Data are representative of two separate
experiments. Asterisks indicate statistically signiﬁcant diﬀerences between the indicated groups.
the IFN-γ mRNA levels recorded were low and akin to
infected control mice, although they are greater than the
levels in uninfected control mice. The levels of IL-4 were also
low and did not vary signiﬁcantly as a result of infection
with P. berghei ANKA or administration of Cry1Ac protein
(Figure 4). In contrast, following infection with P. chabaudi
AS, the levels of IFN-γ were higher in control mice than
in those pretreated with Cry1Ac protoxin. The IFN-γ levels
induced after P. chabaudi AS infection were considerably
lower compared to those elicited following P. berghei ANKA
infection, but they were still higher than those present in
uninfected mice.
In control P. chabaudi AS-infected mice, the levels of IL-4
increased at day 18 PI, while in mice pretreated with Cry1Ac,
the levels of this cytokine did not change (Figure 4). Levels
of IL-2, IL-5 and TNF-α were not modiﬁed by any of these
treatments (results not shown).
3.5. Protoxin Cry1Ac Increases the Levels of Speciﬁc Antibodies
for P. berghei ANKA and P. chabaudi AS in Infected Mice.
Speciﬁc anti-P. berghei ANKA antibodies were induced in
sera from mice infected with the parasite (at days 4 and 8
PI), while sera from control uninfected mice, which were
untreated or received PBS or Cry1Ac alone, did not have
detectable anti-P.berghei ANKA antibodies (Figure 5).
The treatment with protoxin Cry1Ac before infection
increased the levels of IgG1, IgG2a, IgG2b, and IgM in
P. berghei ANKA-infected mice. Interestingly, this increase
was only detected on day 4 PI compared to mice receiving
the vehicle alone. At day 8 PI, similar levels of IgG and
IgM responses were induced in both experimental groups
(Figure 5).
In infected mice pretreated with Cry1Ac, the speciﬁc
anti-P. chabaudi AS IgG response was signiﬁcantly higher on
days 8 and 18 than that elicited in infected mice pretreated
with the vehicle (Figure 6). Regarding the analyses of the
diﬀerent IgG subclasses, speciﬁc responses at day 4 PI of the
four IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) were
alsosigniﬁcantlyhigherinthegroupreceivingCry1Acbefore
the infection compared to the group receiving the vehicle
alone (Figure 5). However, at day 8 PI, the IgG2b responses
detected were higher in the vehicle group with respect to
the Cry1Ac group, while the IgG responses of the rest of the
isotypes recorded were similar between the two groups.6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀect of Cry1Ac on serum cytokines in Plasmodium-infected mice.Mice were treated with Cry1Ac protoxin or PBS once weekly
for four weeks. One day after the last injection, mice were infected with P. berghei ANKA or P. chabaudi AS. On days 4 and 8 PI (a and c)
or days 8 and 18 PI (b and d), three mice from each group were killed, their sera was separated from peripheral blood and the levels of the
cytokines IFN-γ (a and b) and IL-4 (c and d) were measured by cytometric bead array. Data are representative of two separate experiments.
Asterisks indicate statistically signiﬁcant diﬀerences between the indicated groups.
The IgM-speciﬁc response at day 8 PI was signiﬁcantly
higher in the group that received Cry1Ac than in the group
treated with vehicle.
The speciﬁc antibody responses recorded in mice
infectedwithP.bergheiANKA werelower in relation to those
elicited in mice infected with P. chabaudi AS. This result was
expectedsince thelattergroupof micehad a longerperiod of
antigenicstimulation.Inserafromuninfectedmicereceiving
either the vehicle (PBS) or Cry1Ac, speciﬁc anti-P. berghei
ANKA antibodies were not detected.
4. Discussion
Our results demonstrate that administration of the Cry1Ac
protoxin from B. thuringiensis induces protection against
the malaria parasite when it is administered in CBA/Ca
mice before infection with P. chabaudi AS and induces
al o n g e rs u r v i v a lt i m ei nP. berghei ANKA-infected mice
(Figures 1 and 2). Protection was shown by lower levels of
parasitaemia (ﬁrst peak) in groups of mice infected with
either P. chabaudi AS or P. berghei ANKA compared to
control mice. In addition, Cry1Ac protoxin modulated the
mRNA expression of proinﬂammatory cytokines, such as
IFN-γ and TGF-β, and increased the levels of IgG and
IgM in both P. berghei ANKA- and P. chabaudi AS-infected
mice.
Due to the diﬀerent courses of parasitaemia between
CBA/CamiceinfectedwiththelethalP.bergheiANKA,which
killed all of the mice around day 9 PI, and the non-lethal
P. chabaudi AS, the samples were analysed at diﬀerent days
(4 and 8 versus 8 and 18, resp.) to get the best comparison
between both infections.
We evaluated the eﬀect of Cry1Ac protoxin against
Plasmodium i n f e c t i o nb e c a u s ew eh a v ep r e v i o u s l y
described that this protein may be a valuable tool for
the improvement of mucosal vaccines; when Cry1Ac
protoxin is coadministered as an adjuvant, it increases
protective immunity against experimental Naegleria fowleri
meningoencephalitis, an acute fulminant infection initiated
at the nasal mucosa, in mice [13]. Interestingly, intranasal
administration of Cry1Ac alone also had protective eﬀects
against N. fowleri infection, as this treatment increasedJournal of Biomedicine and Biotechnology 7
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Figure 5: Parasite-speciﬁc antibody responses in mice treated with Cry1Ac and infected with P. berghei A N K A .M i c ew e r et r e a t e dw i t h
Cry1Ac protoxin or PBS as described previously and were infected with P. berghei ANKA. At days 4 (white bars) and 8 (grey bars) PI, the sera
of three mice from each group were collected and measured by ELISA for antibody levels. The results are expressed as the mean OD value
± SD (n = 3). Control absorbance values were provided by normal mouse serum (NS) obtained from age- and sex-matched CBA/Ca mice.
Data are representative of two separate experiments. Asterisks indicate statistically signiﬁcant diﬀerences between the indicated groups.
survival, as immunization with amoebal lysates alone did,
suggestingthatCry1Acprotoxinmayboostinnateimmunity.
In addition, it has been reported that Cry1Ac protoxin
enhances the respiratory burst of human monocytes and
neutrophils [24]. Accordingly, our unpublished results sug-
gest that Cry1Ac activates mouse macrophages, inducing the
expressionofthecostimulatorymoleculesB7-1andB7-2and
the production of some proinﬂammatory cytokines (IFN-γ
and MCP-1), but further studies are required to elucidate the
mechanisms involved.
Despite the fact that Cry proteins are not toxic to
vertebrates and Cry1Ac is known to form pores exclusively
in the midgut epithelial cells of lepidopteran insect, the
existence of an unknown receptor in mammals has been
suggested, because Cry1Ac protoxin binds to brush border
membrane vesicles prepared from mouse small intestine in
vitro [14]. The nature of the molecules interacting with Cry
proteins in mammalian enterocytes seems to be diﬀerent
than the receptor glycoproteins described in insects, such
as the 120-kDa aminopeptidase N [11] and the 210-kDa
cadherin-like glycoprotein (Bt-R1) [25] because binding to
itsreceptorwasnotinhibitedbyGalNAc,mannose,orbiotin.
On the other hand, it has been shown that IFN-
γ is able to activate macrophages, which are responsible
for elimination of the the malaria parasite [26–28]. Our
results show that treatment with Cry1Ac protoxin decreased
parasitaemia in mice infected with P. berghei ANKA at day
8 PI. At that time, downregulation of TGF-β expression
and an increase in both mRNA expression and serum levels
of IFN-γ were found (Figures 3 and 4). This ﬁnding is
consistent with a previous report showing that protective
immunity was associated with a decrease in TGF-β and
a concomitant increase in IFN-γ production in P. yoelii
17XL-infected mice [29]. In addition, it has been shown8 Journal of Biomedicine and Biotechnology
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Figure 6: Parasite-speciﬁc antibody responses in mice treated with Cry1Ac and infected with P. chabaudi A S .M i c ew e r et r e a t e dwi t hC ry 1 A c
protoxin or PBS as described previously and were infected with P. chabaudi AS. At days 8 (white bars) and 18 (grey bars) PI, the sera of three
mice from each group were collected and measured by ELISA for antibody levels. The results are expressed as the mean OD value ± SD
(n = 3). Control absorbance values were provided by normal mouse serum (NS) obtained from age- and sex-matched CBA/Ca mice. Data
are representative of two separate experiments. Asterisks indicate statistically signiﬁcant diﬀerences between the indicated groups.
that upregulation of IFN-γ in P. berghei ANKA-infected
mice leads to the activation of macrophage, which increases
parasite elimination [30]. However, mice infected with P.
berghei ANKA in our study were not fully protected, and all
of them died at day 21 PI. A possible explanation for this
ﬁnding is that the eﬀe c to fC r y 1 A cp r o t o x i ni sl i m i t e d ;i t
could promote a decrease in parasitaemia in mice at day 8
PI, which, in turn, diminishes the antigenic stimulation and
downregulates the immunopathology. As the parasite was
not completely eliminated, it started to proliferate again, and
by day 11, PI Cry1Ac protoxin no longer had an eﬀect.
On the other hand, clearance of P. chabaudi in mice
depends ﬁrst on their ability to mount an early proinﬂam-
matory cytokine response and second on their ability to
downregulate the inﬂammatory response before the onset
of the immunopathology [31]. In our study, mice treated
with protoxin Cry1Ac and infected with P. chabaudi AS more
eﬃciently eliminated parasitaemia, despite the fact that this
g r o u pd e m o n s t r a t e dad e c r e a s ei nI F N - γ mRNA expression
that correlated with decreased serum levels of this cytokine
compared to mice treated with PBS (Figures 3 and 4). This
fact could be related to the upregulation of TGF-β, which has
been shown to play a double role in malaria infections; it is
able to lead pro- and anti-inﬂammatory responses that may
downregulatetheproductionofIFN-γ [29].Itisalsopossible
that the improved parasite elimination in the mice treated
with Cry1Ac could be related to higher levels of IgG and IgM
antibodies, which could be associated with better parasite
elimination due to an increase in phagocytosis [32–36].
Treatment with protoxin Cry1Ac before Plasmodium
infection induced a stronger antibody response in CBA/Ca
mice to both Plasmodium berghei ANKA and P. chabaudi
AS infections compared to control mice treated with PBS
(Figures 5 and 6). Currently, the reason for this increase
is not clear; however, this ﬁnding could be explained by a
cross-reaction resulting from molecular similarities betweenJournal of Biomedicine and Biotechnology 9
epitopes of Plasmodium and the Cry1Ac protoxin. We have
performed ELISA assays in which the Cry1Ac protoxin
or P. berghei ANKA antigen was bound to the plate and
several dilutions of P. berghei ANKA immune mice serum
were tested. In these assays, immune sera to P. berghei
ANKA or P. chabaudi AS recognised Cry1Ac protoxin and
developed higher OD values compared to normal mouse
serum (data not shown), strongly suggesting that P. berghei
ANKA and Cry1Ac share common antigens. However,
further study is required to characterise the precise antigens
involved.
Another possible mechanism, in which the pretreatment
with Cry1Ac may increase survival in Plasmodium-infected
mice and may increase both the levels of Plasmodium-
speciﬁc antibodies elicited after the challenge and the levels
of IFN-γ, may involve the activation of innate immune
cells, such as antigen presenting cells, that permit a faster
establishment of adaptive immune responses. In agreement
with this proposal, our unpublished data indicate that
Cry1Ac protoxin activates mouse macrophages, inducing the
expressionofthecostimulatorymoleculesB7-1andB7-2and
the production of proinﬂammatory cytokines.
The isotypes of protective antibodies in Plasmodium
infections are under debate. In general, it is accepted
that IgG1 and IgG2a are protective [37–40]. However, in
some reports, IgG2b or IgG3 are also mentioned as being
protective [41, 42]. In mice, it is well known that IFN-γ,
the principal Th1 eﬀector cytokine, regulates the production
of the opsonising or cytophilic isotype IgG2a [43], which
is in accordance with our results in P. berghei-infected
mice, and that IL-4 is central to the synthesis of IgG1,
while TGF-β is involved in the synthesis of IgG2b [38].
I no u rs t u d y ,w ef o u n dt h a tp r e t r e a t m e n tw i t hC r y 1 A c
protoxin signiﬁcantly increases the IgG subclasses assessed
and IgM in P. chabaudi AS- or P. berghei ANKA-infected
mice, which could be associated with parasite clearance
because it has been shown that antibody responses play
a critical role in immune protection against Plasmodium
in asexual blood stages. This role has been demonstrated
by passive transfer experiments using sera or puriﬁed
immunoglobulins from adults residing in areas with hyper-
endemic malaria [44, 45]. However, the mechanisms by
which malaria-speciﬁc antibodies interfere with the develop-
ment and/or multiplication of the asexual stages of human
Plasmodia are still unclear. It has been postulated that
antibodies inhibit parasite growth in cooperation either with
monocytes or neutrophils via antibody-dependent cellular
inhibition [46, 47] or by immunophagocytosis through Fc
receptors expressed on the cell surface after binding their
parasite target [48]. In addition, a correlation between
immune protection and the ability of serum to mediate
opsonisation of infected erythrocytes has been described
[49]. Further studies are required to clarify the mecha-
nisms involved in boosting the innate immunity against
malaria.
Like most adjuvants Cry1Ac protoxin might exert its
activity by activating innate immune cells. The data pre-
sented in this study suggest that pretreatment with this pro-
tein could lead to design prophylactic strategies to improve
resistance against malaria infections. However, further stud-
ies are required to clarify the mechanisms involved in
boosting the innate immunity against Plasmodium infection.
Acknowledgments
The authors thank Armando Cervantes for his help with
the statistical analysis. This work was supported by the
following Grants: PAPIIT IN214007, IN220310, IN221807,
and CONACYT 080920.
References
[1] R. W. Snow, C. A. Guerra, A. M. Noor, H. Y. Myint, and
S. I. Hay, “The global distribution of clinical episodes of
Plasmodium falciparum malaria,” Nature, vol. 434, no. 7030,
pp. 214–217, 2005.
[2] P.C.BullandK.Marsh,“TheroleofantibodiestoPlasmodium
falciparum-infected-erythrocyte surface antigens in naturally
acquiredimmunitytomalaria,”TrendsinMicrobiology,vol.10,
no. 2, pp. 55–58, 2002.
[3] D.L.Doolan,C.Doba˜ no,andJ.K.Baird,“Acquiredimmunity
to Malaria,” Clinical Microbiology Reviews, vol. 22, no. 1, pp.
13–36, 2009.
[4] K. Artavanis-Tsakonas, J. E. Tongren, and E. M. Riley, “The
war between the malaria parasite and the immune system:
immunity, immunoregulation and immunopathology,” Clini-
calandExperimentalImmunology,vol.133,no.2,pp.145–152,
2003.
[ 5 ]B .M .G r e e n w o o d ,A .M .B r a d l e y - M o o r e ,A .D .B r y c e s o n ,a n d
A. Palit, “Immunosuppression in children with malaria,” The
Lancet, vol. 1, no. 7743, pp. 169–172, 1972.
[6] D. B. Whitmore, “Suppression of the immune response to
heterologous erythrocytes in mice infected with Plasmodium
berghei berghei,” Transactions of the Royal Society of Tropical
Medicine and Hygiene, vol. 66, no. 1, pp. 5–6, 1972.
[7] B. C. Urban, R. Ing, and M. M. Stevenson, “Early interactions
between blood-stage Plasmodium parasites and the immune
system,” Current Topics in Microbiology and Immunology, vol.
297, pp. 25–70, 2005.
[8] K. Grech, K. Watt, and A. F. Read, “Host-parasite interactions
for virulence and resistance in a malaria model system,”
Journal of Evolutionary Biology, vol. 19, no. 5, pp. 1620–1630,
2006.
[9] M. N. Wykes, X. Q. Liu, L. Beattie, et al., “Plasmodium strain
determines dendritic cell function essential for survival from
malaria,” PLoS Pathogens, vol. 3, no. 7, article e96, 2007.
[10] H. Hofte and H. R. Whiteley, “Insecticidal crystal proteins of
Bacillus thuringiensis,” Microbiological Reviews, vol. 53, no. 2,
pp. 242–255, 1989.
[11] P. J. K. Knight, N. Crickmore, and D. J. Ellar, “The receptor
for Bacillus thuringiensis CrylA(c) delta-endotoxin in the
brush border membrane of the lepidopteran Manduca sexta
is aminopeptidase N,” Molecular Microbiology, vol. 11, no. 3,
pp. 429–436, 1994.
[12] E. Schnepf, N. Crickmore, J. Van Rie, et al., “Bacillus
thuringiensis and its pesticidal crystal proteins,” Microbiology
and Molecular Biology Reviews, vol. 62, no. 3, pp. 775–806,
1998.
[13] S. Rojas-Hernandez, M. A. Rodriguez-Monroy, R. Lopez-
Revilla, A. A. Resendiz-Albor, and L. Moreno-Fierros,
“Intranasal coadministration of the Cry1Ac protoxin with10 Journal of Biomedicine and Biotechnology
amoebal lysates increases protection against Naegleria fowleri
meningoencephalitis,” Infection and Immunity,v o l .7 2 ,n o .8 ,
pp. 4368–4375, 2004.
[14] R. I. V´ azquez-Padr´ on, L. Moreno-Fierros, L. Neri-Baz´ an,
G. A. de la Riva, and R. L´ opez-Revilla, “Intragastric and
intraperitoneal administration of Cry1Ac protoxin from
Bacillus thuringiensis induces systemic and mucosal antibody
responses in mice,” Life Sciences, vol. 64, no. 21, pp. 1897–
1912, 1999.
[15] G. G. Guerrero and L. Moreno-Fierros, “Carrier potential
propertiesofBacillusthuringiensisCry1Atoxinsforadiphthe-
ria toxin epitope,” Scandinavian Journal of Immunology, vol.
66, no. 6, pp. 610–618, 2007.
[16] G. G. Guerrero, W. M. Russell, and L. Moreno-Fierros,
“Analysis of the cellular immune response induced by Bacillus
thuringiensis Cry1A toxins in mice: eﬀect of the hydrophobic
motif from diphtheria toxin,” Molecular Immunology, vol. 44,
no. 6, pp. 1209–1217, 2007.
[17] S. Roetynck, M. Baratin, S. Johansson, C. Lemmers, E.
Vivier, and S. Ugolini, “Natural killer cells and malaria,”
Immunological Reviews, vol. 214, no. 1, pp. 251–263, 2006.
[18] K. Artavanis-Tsakonas and E. M. Riley, “Innate immune
response to malaria: rapid induction of IFN-γ from human
NK cells by live Plasmodium falciparum-infected erythro-
cytes,” Journal of Immunology, vol. 169, no. 6, pp. 2956–2963,
2002.
[19] A. Z. Ge, R. M. Pﬁster, and D. H. Dean, “Hyperexpression
of a Bacillus thuringiensis delta-endotoxin-encoding gene in
Escherichia coli: properties of the product,” Gene, vol. 93, no.
1, pp. 49–54, 1990.
[20] M. M. Bradford, “A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein dye binding,” Analytical Biochemistry, vol.
72, no. 1-2, pp. 248–254, 1976.
[21] M. Legorreta-Herrera, M. L. Ventura-Ayala, R. N. Licona-
Chavez, I. Soto-Cruz, and F. F. Hernandez-Clemente, “Early
treatment during a primary malaria infection modiﬁes the
developmentofcrossimmunity,”ParasiteImmunology,vol.26,
no. 1, pp. 7–17, 2004.
[22] S. Campino, S. Bagot, M.-L. Bergman, et al., “Genetic control
of parasite clearance leads to resistance to Plasmodium berghei
ANKA infection and confers immunity,” Genes and Immunity,
vol. 6, no. 5, pp. 416–421, 2005.
[23] A. Shibui, N. Hozumi, C. Shiraishi, et al., “CD4+ Tc e l l
response in early erythrocytic stage malaria: Plasmodium
berghei infection in BALB/c and C57BL/6 mice,” Parasitology
Research, vol. 105, no. 1, pp. 281–286, 2009.
[24] A.R.Rodriguez-Orozco,G.RicoRosillo,andR.Lopez-Revilla,
“The eﬀect of Cry1Ac on human monocytes and neutrophil
activation,”AllergyandClinicalImmunologyInternational,vol.
17, no. 2, pp. 64–65, 2005.
[25] Y. Nagamatsu, T. Koike, K. Sasaki, A. Yoshimoto, and Y.
Furukawa, “The cadherin-like protein is essential to speciﬁcity
determination and cytotoxic action of the Bacillus thuringien-
sis insecticidal CryIAa toxin,” FEBS Letters, vol. 460, no. 2, pp.
385–390, 1999.
[26] C. F. Ockenhouse, S. Schulman, and H. L. Shear, “Induction
of crisis forms in the human malaria parasite Plasmod-
ium falciparum by γ-interferon-activated, monocyte-derived
macrophages,” Journal of Immunology, vol. 133, no. 3, pp.
1601–1608, 1984.
[27] T. Yoneto, T. Yoshimoto, C.-R. Wang, et al., “Gamma
interferon production is critical for protective immunity
to infection with blood-stage Plasmodium berghei XAT but
neither NO production nor NK cell activation is critical,”
Infection and Immunity, vol. 67, no. 5, pp. 2349–2356, 1999.
[28] H. L. Shear, R. Srinivasan, T. Nolan, and C. Ng, “Role of IFN-
γ in lethal and nonlethal malaria in susceptible and resistant
murine hosts,” Journal of Immunology, vol. 143, no. 6, pp.
2038–2044, 1989.
[29] F. M. Omer, J. B. de Souza, and E. M. Riley, “Diﬀerential
induction of TGF-β regulates proinﬂammatory cytokine pro-
duction and determines the outcome of lethal and nonlethal
Plasmodiumyoeliiinfections,”JournalofImmunology,vol.171,
no. 10, pp. 5430–5436, 2003.
[30] K. N. Couper, D. G. Blount, J. C. R. Hafalla, N. Van Rooijen,
J. B. de Souza, and E. M. Riley, “Macrophage-mediated
but gamma interferon-independent innate immune responses
control the primary wave of Plasmodium yoelii parasitemia,”
Infection and Immunity, vol. 75, no. 12, pp. 5806–5818, 2007.
[31] M. M. Stevenson and E. M. Riley, “Innate immunity to
malaria,” Nature Reviews Immunology, vol. 4, no. 3, pp. 169–
180, 2004.
[32] R. J. Pleass, S. A. Ogun, D. H. McGuinness, J. G. J. Van De
Winkel, A. A. Holder, and J. M. Woof, “Novel antimalarial
antibodies highlight the importance of the antibody Fc region
in mediating protection,” Blood, vol. 102, no. 13, pp. 4424–
4430, 2003.
[ 3 3 ]A .E .T e b o ,P .G .K r e m s n e r ,a n dA .J .F .L u t y ,“ F c γ receptor-
mediated phagocytosis of Plasmodium falciparum-infected
erythrocytes in vitro,” Clinical and Experimental Immunology,
vol. 130, no. 2, pp. 300–306, 2002.
[ 3 4 ]M .M .M o t a ,K .N .B r o w n ,A .A .H o l d e r ,a n dW .J a r r a ,
“Acute Plasmodium chabaudi chabaudi malaria infection
induces antibodies which bind to the surfaces of parasitized
erythrocytes and promote their phagocytosis by macrophages
invitro,”Infectionand Immunity,vol.66,no.9,pp.4080–4086,
1998.
[ 3 5 ]Y .P e n g ,R .K o w a l e w s k i ,S .K i m ,a n dK .B .E l k o n ,“ T h er o l eo f
IgM antibodies in the recognition and clearance of apoptotic
cells,”MolecularImmunology,vol.42,no.7,pp.781–787,2005.
[36] H. L. Shear, R. S. Nussenzweig, and C. Bianco, “Immune
phagocytosis in murine malaria,” Journal of Experimental
Medicine, vol. 149, no. 6, pp. 1288–1298, 1979.
[37] B. D. Akanmori, S. Waki, and M. Suzuki, “Immunoglobulin
G ( 2 a )i s o t y p em a yh a v eap r o t e c t i v er o l ei nPlasmodium
berghei NH65 infection in immunised mice,” Parasitology
Research, vol. 80, no. 8, pp. 638–641, 1994.
[38] S. Waki, S. Uehara, K. Kanbe, H. Nariuch, and M. Suzuki,
“Interferon-gamma and the induction of protective IgG2a
antibodies in non-lethal Plasmodium berghei infections of
mice,”ParasiteImmunology,vol.17,no.10,pp.503–508,1995.
[39] J. Langhorne, K. J. Kim, and R. Asofsky, “Distribution of
immunoglobulin isotypes in the nonspeciﬁc B-cell response
induced by infection with Plasmodium chabaudi adami and
Plasmodium yoelii,” Cellular Immunology,v o l .9 0 ,n o .1 ,p p .
251–257, 1985.
[40] R. A. Cavinato, K. R. B. Bastos, L. R. Sardinha, R. M. Elias,
J. M. Alvarez, and M. R. D’Imp´ erio Lima, “Susceptibility of
thediﬀerentdevelopmentalstagesoftheasexual(schizogonic)
erythrocyte cycle of Plasmodium chabaudi chabaudi to hyper-
immune serum, immunoglobulin (Ig)G1, IgG2a and F(ab
 )2
fragments,” Parasite Immunology, vol. 23, no. 11, pp. 587–597,
2001.
[41] L. Kedzierski, C. G. Black, A. W. Stowers, M. W. Goschnick, D.
C. Kaslow, and R. L. Coppel, “Comparison of the protective
eﬃcacy of yeast-derived and Escherichia coli-derived recom-
binant merozoite surface protein 4/5 against lethal challengeJournal of Biomedicine and Biotechnology 11
by Plasmodium yoelii,” Vaccine, vol. 19, no. 32, pp. 4661–4668,
2001.
[42] O. Garraud, S. Mahanty, and R. Perraut, “Malaria-speciﬁc
antibody subclasses in immune individuals: a key source of
information for vaccine design,” Trends in Immunology, vol.
24, no. 1, pp. 30–35, 2003.
[43] C. M. Snapper and W. E. Paul, “Interferon-γ and B cell stim-
ulatory factor-1 reciprocally regulate Ig isotype production,”
Science, vol. 236, no. 4804, pp. 944–947, 1987.
[44] S. Cohen, I. A. McGregor, and S. Carrington, “Gamma-
globulin and acquired immunity to human malaria,” Nature,
vol. 192, no. 4804, pp. 733–737, 1961.
[45] A. Sabchareon, T. Burnouf, D. Ouattara, et al., “Parasitologic
and clinical human response to immunoglobulin adminis-
tration in falciparum malaria,” American Journal of Tropical
Medicine and Hygiene, vol. 45, no. 3, pp. 297–308, 1991.
[46] H. Bouharoun-Tayoun, P. Attanath, A. Sabchareon, T. Chong-
suphajaisiddhi, and P. Druilhe, “Antibodies that protect
humans against Plasmodium falciparum blood stages do not
on their own inhibit parasite growth and invasion in vitro, but
act in cooperation with monocytes,” Journal of Experimental
Medicine, vol. 172, no. 6, pp. 1633–1641, 1990.
[47] H. Bouharoun-Tayoun, C. Oeuvray, F. Lunel, and P. Druilhe,
“Mechanisms underlying the monocyte-mediated antibody-
dependent killing of Plasmodium falciparum asexual blood
stages,” Journal of Experimental Medicine, vol. 182, no. 2, pp.
409–418, 1995.
[48] A.Ferrante,L.Kumaratilake,C.M.Rzepczyk,andJ.-M.Dayer,
“Killing of Plasmodium falciparum by cytokine activated
eﬀector cells (neutrophils and macrophages),” Immunology
Letters, vol. 25, no. 1–3, pp. 179–187, 1990.
[49] H. Groux and J. Gysin, “Opsonization as an eﬀector mech-
anism in human protection against asexual blood stages of
Plasmodium falciparum: functional role of IgG subclasses,”
Research in Immunology, vol. 141, no. 6, pp. 529–542, 1990.